Current and Future Therapies for Hepatitis C Virus Infection
Top Cited Papers
- 16 May 2013
- journal article
- review article
- Published by Massachusetts Medical Society in New England Journal of Medicine
- Vol. 368 (20) , 1907-1917
- https://doi.org/10.1056/nejmra1213651
Abstract
Only 20 years after the discovery of the hepatitis C virus, a cure is now likely for most people with chronic infection. This review considers current therapy and the present landscape of drug development for hepatitis C.Keywords
This publication has 72 references indexed in Scilit:
- Case report of successful peginterferon, ribavirin, and daclatasvir therapy for recurrent cholestatic hepatitis C after liver retransplantationLiver Transplantation, 2012
- Review and management of drug interactions with boceprevir and telaprevirHepatology, 2012
- Preliminary Study of Two Antiviral Agents for Hepatitis C Genotype 1New England Journal of Medicine, 2012
- Identification of the Niemann-Pick C1–like 1 cholesterol absorption receptor as a new hepatitis C virus entry factorNature Medicine, 2012
- An update on treatment of genotype 1 chronic hepatitis C virus infection: 2011 practice guideline by the American Association for the Study of Liver DiseasesHepatology, 2011
- Potent inhibitors of hepatitis C core dimerization as new leads for anti-hepatitis C agentsBioorganic & Medicinal Chemistry Letters, 2011
- Boceprevir for Previously Treated Chronic HCV Genotype 1 InfectionNew England Journal of Medicine, 2011
- Outcome of Sustained Virological Responders With Histologically Advanced Chronic Hepatitis C†,‡,§,¶Hepatology, 2010
- Multiple variants in toll-like receptor 4 gene modulate risk of liver fibrosis in Caucasians with chronic hepatitis C infectionJournal of Hepatology, 2009
- Hepatic gene expression during treatment with peginterferon and ribavirin: Identifying molecular pathways for treatment responseHepatology, 2007